Sumanta Pal

Abstract CT011: A phase 1 multicenter study (TRAVERSE) evaluating the safety and efficacy of ALLO-316 following conditioning regimen in pts with advanced or metastatic clear cell renal cell carcinoma (ccRCC)

Samer A. Srour, Ritesh R. Kotecha, Brendan D. Curti et al. · Cancer Research · 2023 · 35 citations

Immunology, Immunoediting, Immunotherapeutics +19

558 CTX130 allogeneic CRISPR-Cas9–engineered chimeric antigen receptor (CAR) T cells in patients with advanced clear cell renal cell carcinoma: Results from the phase 1 COBALT-RCC study

Sumanta Pal, Ben Tran, John Haanen et al. · Regular and Young Investigator Award Abstracts · 2022 · 28 citations · Full text

Immunology, Immunoediting, Immunotherapeutics +21

Co-primary endpoint analysis of HCRN GU 16-257: Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle-invasive bladder cancer (MIBC).

Matt D. Galsky, Siamak Daneshmand, Sara Lewis et al. · Journal of Clinical Oncology · 2023 · 17 citations

Surgical Oncology, Multimodality, Bladder Tumor +21

Optimal treatment by invoking biologic clusters in renal cell carcinoma (OPTIC RCC).

Yu‐Wei Chen, Katy Beckermann, Scott M. Haake et al. · Journal of Clinical Oncology · 2023 · 15 citations

Ccrcc Tumors, Cancer Management, Renal Pathology +22